Flow cytometric detection and quantification of CD56 (neural cell adhesion molecule, NCAM) expression in diffuse large B cell lymphomas and review of the literature

Histopathology

Volumn 60, Issue 3, 2012, Pages 452-459

  Stacchini, Alessandra ^a   Barreca, Antonella ^a   Demurtas, Anna ^a   Aliberti, Sabrina ^a   Di Celle, Paola Francia ^b   Novero, Domenico ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Center for Experimental Research and Medical Studies CERMS   (Italy)

Author keywords

CD56; Flow cytometry; Immunohistochemistry; Large B cell lymphoma

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; KI 67 ANTIGEN; LEUKOSIALIN; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 2; PROTEIN BCL 6;

ADOLESCENT; ADULT; AGED; ARTICLE; CYTOPLASM; FLOW CYTOMETRY; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ADOLESCENT; AGED; ANTIGENS, CD56; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HUMANS; LYMPH NODES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856249135     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04098.x     Document Type: Article

References (35)

1. Ditlevsen DK, Povlsen GK, Berezin V, Bock E. NCAM-induced intracellular signaling revisited. J. Neurosci. Res. 2007; 86; 727-743.
2. MaClain DA, Edelman GM. A neural cell adhesion molecule from human brain. Proc. Natl. Acad. Sci. 1982; 79; 6380-6384.
3. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J. Immunol. 1983; 130; 2947-2951.
4. Rees RC. MHC restricted and non-restricted killer lymphocytes. Blood Rev. 1990; 4; 204-210.
5. Martin TR, Mongovin SM, Tobias PE et al. The CD14 differentiation antigen mediates the development of endotoxin responsiveness during differentiation of mononuclear phagocytes. J. Leukoc. Biol. 1994; 56; 1-9.
6. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87; 1207-1210.
7. Van Camp B, Durie BGM, Spier C et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (Nkh-1;Leu 19). Blood 1990; 76; 377-382.
8. Mann KP, DeCastro CM, Liu J, Moore JO, Bigner SH, Traweek ST. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am. J. Clin. Pathol. 1997; 107; 653-660.
9. Ravandi F, Cortes J, Estrov Z et al. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk. Res. 2002; 26; 643-649.
10. Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Gragan TM. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual site of involvement. Blood 1992; 79; 2432-2437.
11. Ng CS, Lo ST, Chan WC. CD56+ putative natural killer cell lymphomas: production of cytolytic effectors and related proteins mediating tumor cell apoptosis? Hum. Pathol. 1997; 28; 1276-1282.
12. Weisberger J, Gorczyca W, Kinney MC. CD56-positive large B-cell lymphoma. Appl. Immunohistochem. Mol. Morphol. 2006; 14; 369-374.
13. Muroi K, Omine K, Kuribara R et al. CD56 expression in B-cell lymphoma. Leuk. Res. 1998; 22; 201-202.
14. Sekita T, Tamaru J, Isobe K et al. Diffuse large B cell lymphoma expressing the natural killer cell marker CD56. Pathol. Int. 1999; 49; 752-758.
15. Otsuka M, Yakushijin Y, Hamada M, Hato T, Yasakawa M, Fujita S. Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance. Br. J. Haematol. 2004; 127; 416-424.
16. Isobe Y, Sugimoto K, Takeuchi K et al. Neural cell adhesion molecule (CD56)-positive B cell lymphoma. Eur. J. Haematol. 2007; 79; 166-169.
17. Gomyo H, Kajimoto K, Miyata Y et al. CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression. Hematology 2010; 15; 157-161.
18. Chen B, Sun WY, Zhang G. CD56-positive diffuse large B-cell lymphoma: report of a case. Zhonghua Bing Li Xue Za Zhi 2010; 39; 343-344.
19. Hammer RD, Vnencak-Jones CL, Manning BS, Glick AD, Kinney MC. Microvillous lymphomas are B-cell neoplasms that frequently express CD56. Mod. Pathol. 1998; 11; 239-246.
20. Swerdlow H, Campos E, Harris NL et al. eds. World Health Organization classification of tumours of haemopoietic and lymphoid tissues, 4th edn. Lyon, France: IARC Press, 2008; 233-237.
21. Manazza AD, Bonello L, Pagano M et al. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. Am. J. Clin. Pathol. 2005; 124; 182-190.
22. Demurtas A, Aliberti S, Bonello L et al. Usefulness of multiparametric flow cytometry in detecting composite lymphoma: study of 17 cases over a 12-year period. Am. J. Clin. Pathol. 2011; 135; 541-555.
23. Stacchini A, Chiarle R, Antinoro V, Demurtas A, Novero D, Palestro G. Expression of the CD31 antigen in normal B-cells and non Hodgkin's lymphomas J. Biol. Reg. Homeost. Agents 2003; 17; 308-315.
24. Diss TC, Peng H, Wotherspoon AC, Isaacson PG, Pan L. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J. Pathol. 1993; 169; 291-295.
25. Carulli G, Stacchini A, Marini A et al. Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration. Am. J. Clin. Pathol. 2009; 132; 186-190.
26. Arrondini M, Barreca A, Aliberti S et al. CD4-positive diffuse large B cell lymphoma identified by flow cytometry: two case reports. Int. J. Hematol. 2010; 92; 198-203.
27. Inaba T, Shimazaki C, Sumikuma T, Nakagawa M. T-cell associated antigen-positive B-cell lymphoma. Leuk. Lymphoma 2001; 42; 1161-1171.
28. Schmidt CJ, Domenico L, Ward P, Barcos MP, Stewart CC. Aberrant antigen expression detected by multiparameter three color flow cytometry in intermediate and high grade B-cell lymphomas. Leuk. Lymphoma 1999; 34; 539-544.
29. Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99; 815-821.
30. Rutishauser U, Acheson A, Hall AK, Mann DM, Sunshine J. The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science 1988; 240; 53-57.
31. Bataille R, Jego G, Robillard N et al. The phenotype of normal, and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 2006; 91; 1234-1240.
32. Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J. Clin. Oncol. 1995; 13; 1800-1816.
33. Chang H, Brandwein J, Yi QL, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior outcome. Leuk. Res. 2004; 28; 1007-1011.
34. Zeromski J, Nyczak E, Dyszkiewicz W. Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading. Folia Histochem. Cytobiol. 2001; 39; 36-37.
35. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J. 2003; 22; 18-23.